Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the Phase III TAMARIS trial evaluating the investigational angiogenic therapy NV1FGF (riferminogen pecaplasmid) did not meet its primary endpoint. The primary endpoint was to demonstrate the superiority of NV1FGF vs. placebo in the...